December 07, 2020 16:00 ET | Source: INVENTIVA
multilang-release
Daix (France), December 7, 2020 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the publication of a scientific paper on the beneficial effects of lanifibranor on experimental advanced chronic liver disease (ACLD) by the peer-reviewed scientific journal Journal of Hepatology.
The article, entitled The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease, discusses the effects of Inventivas lead drug candidate lanifibranor, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist, in two distinct pre-clinical models of cirrhosis and in human liver cells from cirrhotic patients. The objective of the underlying studies was to evaluate the therapeutic potential of lanifibranor for the treatment of advanced cirrhosis.
Cirrhosis originates from a sustained hepatic injury that can vary in nature, with excessive alcohol consumption, unhealthy dietary habits and hepatitis B and C virus infections being the most common causes. As a consequence of long-term liver injury, tissue wound healing mechanisms may become deregulated, leading to hepatic fibrosis, which can ultimately progress to decompensated cirrhosis and, in some cases, hepatocellular carcinoma.1
The results of the pre-clinical studies show that lanifibranor improved portal hypertension, fibrosis and liver vascular resistance, three frequent and severe clinical syndromes associated with cirrhosis. The drug candidate also reduced ascites, sinusoidal capillarization, liver sinusoidal endothelial cells (LSEC) and hepatic stellate cells (HSC) activated phenotypes as well as microvascular function and liver inflammation. Furthermore, the results show that all three PPAR isoforms were downregulated in both cirrhotic patients as well as in the pre-clinical models.
Moreover, differential expression of PPAR isoforms was observed in different liver cell types, emphasizing the importance of targeting all three isoforms for the treatment of cirrhosis. Finally, the findings also indicate that lanifibranor improved the phenotypes of isolated hepatocytes and hepatic stellate cells from cirrhotic patients, suggesting that the positive effects observed in both pre-clinical models could be translated to these patients. Pierre Broqua, CSO and cofounder of Inventiva, commented: We are very pleased to see our latest pre-clinical results on lanifibranor for the treatment of cirrhosis published in the renowned Journal of Hepatology. This scientific paper clearly illustrates that lanifibranor significantly improves key features of this severe disease, which still lacks a safe and effective treatment. The beneficial effects are based on our lead drug candidate lanifibranors capacity to target all three PPAR isoforms concomitantly and further encourage its clinical evaluation for the treatment of cirrhosis.
Dr Jordi Gracia-Sancho, Head of the Liver Vascular Biology Team of IDIBAPS Hospital Clnic de Barcelona and co-author of the article, added: These studies, which combine two pre-clinical models of cirrhosis and human liver cells cultured in advanced in vitro systems, show that the pan-PPAR agonist lanifibranor improves the functionality of the cells that compose the liver microcirculatory system, leading to an improvement in portal hypertension and fibrosis. Considering the lack of treatments for advanced chronic liver disease, and its most deleterious complication portal hypertension, the findings included in this manuscript shed light on the way to develop novel therapies for patients with chronic hepatopathies.
Publication details
About lanifibranor
Lanifibranor, Inventivas lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferatoractivated receptor (PPAR) isoforms, which are wellcharacterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a wellbalanced activation of PPAR and PPAR, and a partial activation of PPAR. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only panPPAR agonist in clinical development. Inventiva believes that lanifibranors moderate and balanced panPPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and preclinical studies to date. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.
Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a whollyowned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com
Contacts
Inventiva Frdric Cren Chairman & CEO info@inventivapharma.com +33 3 80 44 75 00
Brunswick Group Yannick Tetzlaff / Tristan Roquet Montegon / Aude Lepreux Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83
Westwicke, an ICR Company Patricia L. Bank Investor relations patti.bank@westwicke.com +1415513 1284
Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to Inventivas clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, believes, anticipates, expects, intends, plans, seeks, estimates, may, will and continue and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventivas business, preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document filed with the Autorit des Marchs Financiers on June 19, 2020 under n D.20-0551 and its amendment filed on July 10, 2020 under n D. 20-0551-A01 as well as the half-year financial report on June 30, 2020 for additional information in relation to such factors, risks and uncertainties.
Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.
1 Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014;14:181194.
2 Zoe Boyer-Diaz: MSc, Barcelona Liver Bioservices, Barcelona, Spain.
3 Peio Aristu-Zabalza: MSc, Barcelona Liver Bioservices, Barcelona, Spain.
4 Mara Andrs-Rozas: MSc, Barcelona Liver Bioservices, Barcelona, Spain.
5 Claude Robert: MSc, Inventiva, Daix, France.
6 Mart Ortega-Ribera: MSc, Liver Vascular Biology Research Group, IDIBAPS, Barcelona, Spain.
7 Anabel Fernndez-Iglesias: PhD, Liver Vascular Biology Research Group, IDIBAPS, Barcelona, Spain & PhD, CIBEREHD, Madrid, Spain.
8 Pierre Broqua: PhD, Inventiva, Daix, France.
9 Jean-Louis Junien: PhD, Inventiva, Daix, France.
10 Guillaume Wettstein: PhD, Inventiva, Daix, France.
11 Jaime Bosch: MD & PhD, Liver Vascular Biology Research Group, IDIBAPS, Barcelona, Spain, CIBEREHD, Madrid, Spain, Hepatology, Department of Biomedical Research, University of Bern, Bern, Switzerland.
12 Jordi Gracia-Sancho: PhD, Barcelona Liver Bioservices, Barcelona, Spain, Liver Vascular Biology Research Group, IDIBAPS, Barcelona, Spain, CIBEREHD, Madrid, Spain, Hepatology, Department of Biomedical Research, University of Bern, Bern, Switzerland.
- Vascular Cell and Molecular Biology | Center for Vascular Biology | Weill Cornell ... - April 13th, 2018 [April 13th, 2018]
- APVBO-Asia Pacific Vascular Biology Organization Conference - April 18th, 2018 [April 18th, 2018]
- Vascular Biology Conferences | Vascular Surgery ... - May 5th, 2018 [May 5th, 2018]
- Vascular Discovery: From Genes to Medicine - May 7th, 2018 [May 7th, 2018]
- 2019 Vascular Cell Biology Conference GRC - May 26th, 2018 [May 26th, 2018]
- Biology 211: Taxonomy of Flowering Plants - June 7th, 2018 [June 7th, 2018]
- esm-evbo2019.org - Menu - July 27th, 2018 [July 27th, 2018]
- Vascular Biology | Pulmonary, Allergy, Sleep & Critical ... - November 16th, 2018 [November 16th, 2018]
- Lower vascular plant | biology | Britannica.com - November 18th, 2018 [November 18th, 2018]
- Vascular Biology - NAVBO - November 20th, 2018 [November 20th, 2018]
- 2019 Cerebral Vascular Biology Conference - cvent.com - November 21st, 2018 [November 21st, 2018]
- PPARs and Their Emerging Role in Vascular Biology ... - November 26th, 2018 [November 26th, 2018]
- Vascular Biology Chicago Medicine - November 30th, 2018 [November 30th, 2018]
- Vascular Biology | Society for Vascular Surgery - November 30th, 2018 [November 30th, 2018]
- Vascular Biology 2018 - NAVBO - December 19th, 2018 [December 19th, 2018]
- Vascular Biology 2019 - NAVBO - December 20th, 2018 [December 20th, 2018]
- Vascular Biology - January 22nd, 2019 [January 22nd, 2019]
- pvb2019.org Plant Vascular Biology Conference 2019 - January 31st, 2019 [January 31st, 2019]
- Plant Physiology | Basic Biology - March 12th, 2019 [March 12th, 2019]
- Awards - esm-evbo2019.org - April 23rd, 2019 [April 23rd, 2019]
- Medication and Exercise to Prevent Muscle Loss - Next Avenue - September 24th, 2019 [September 24th, 2019]
- A Snail as Fast as a Bullet, and Other Darwin-Defying Marvels - Discovery Institute - September 24th, 2019 [September 24th, 2019]
- Nature up close: Life in the Humboldt Penguin National Reserve - CBS News - September 24th, 2019 [September 24th, 2019]
- Oklahoma new hires and promotions announced - Oklahoman.com - September 24th, 2019 [September 24th, 2019]
- Quinn Capers IV, MD - TCTMD - September 24th, 2019 [September 24th, 2019]
- Cardiovascular Repair And Reconstruction Devices Market Global Industry Insights by Top Vendors, Growth, Revenue and Forecast Outlook 2019-2025 -... - September 26th, 2019 [September 26th, 2019]
- Four health projects at Boston Childrens Hospital that could help adults - The Boston Globe - September 30th, 2019 [September 30th, 2019]
- Research Officer/ Postdoctoral Researcher - The Conversation AU - October 16th, 2019 [October 16th, 2019]
- UNSW skin cancer researcher Levon Khachigian hit with string of retractions - ABC News - October 16th, 2019 [October 16th, 2019]
- Michal Wszola: We Expect to Transplant the Bioprinted Bionic Pancreas in Three to Five Years - 3DPrint.com - October 24th, 2019 [October 24th, 2019]
- 'The Blob': This mysterious 'smart' slime can solve puzzles and make decisions - CNBC - October 24th, 2019 [October 24th, 2019]
- University of Maryland and DOD collaborate to study Tick-borne Infections using 3-D models of human blood vessels - Outbreak News Today - November 19th, 2019 [November 19th, 2019]
- Submerged Vegetation Mirrors Coast's Health - Coastal Review Online - November 19th, 2019 [November 19th, 2019]
- Another health warning for e-cigarette users that has nothing to do with lung disease - MarketWatch - November 19th, 2019 [November 19th, 2019]
- E-Cigarettes Take a Dangerous Toll on Heart Health - DocWire News - November 19th, 2019 [November 19th, 2019]
- Vascular biology Department of Surgery College of ... - November 19th, 2019 [November 19th, 2019]
- US Nobel laureates tell us what they think about cancer research, moonshots, the dark side, funding, meritocracy, herd mentality, Trump, and joy - The... - November 21st, 2019 [November 21st, 2019]
- Growing Organs in the Lab: One Step Closer to Reality - BioSpace - November 21st, 2019 [November 21st, 2019]
- Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock - Business Wire - November 21st, 2019 [November 21st, 2019]
- Another Study Suggests E-cigarettes Hurt Heart Health More Than Regular Cigarettes - Science Times - November 21st, 2019 [November 21st, 2019]
- Cleveland Clinic awarded $12 million by NIH to study the link between gut microbes and heart disease - Crain's Cleveland Business - November 21st, 2019 [November 21st, 2019]
- JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD) - Yahoo Finance - November 27th, 2019 [November 27th, 2019]
- Germ-free lungs of newborn mice are partially protected against hyperoxia - The Mix - November 27th, 2019 [November 27th, 2019]
- Bethesda Health Physician Group Welcomes Fellowship-Trained Endocrine Surgeon Jessica L. Buicko, MD, to Its Team - The Boca Raton Tribune - November 27th, 2019 [November 27th, 2019]
- 9 Harvard researchers named AAAS Fellows Harvard - Harvard Gazette - November 27th, 2019 [November 27th, 2019]
- Top Technical Advances of 2019 - The Scientist - December 29th, 2019 [December 29th, 2019]
- Growing up Tyrannosaurus rex: Osteohistology refutes the pygmy Nanotyrannus and supports ontogenetic niche partitioning in juvenile Tyrannosaurus -... - January 2nd, 2020 [January 2nd, 2020]
- UCC currently taking applicants for 21 jobs with some incredible pay - Cork Beo - January 2nd, 2020 [January 2nd, 2020]
- Vascular Biology | Surgery Research | Michigan Medicine ... - January 2nd, 2020 [January 2nd, 2020]
- Sandy Bottom wetlands to receive protection for 'national ecological significance' - Citizen Times - January 14th, 2020 [January 14th, 2020]
- Why biotech is a boon for patients and investors - Spear's WMS - January 14th, 2020 [January 14th, 2020]
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related... - January 14th, 2020 [January 14th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 Dagoretti News - Dagoretti News - January 18th, 2020 [January 18th, 2020]
- Scientists revealed the oldest known scorpion on Earth - Tech Explorist - January 18th, 2020 [January 18th, 2020]
- How biology creates networks that are cheap, robust, and efficient - Penn: Office of University Communications - January 18th, 2020 [January 18th, 2020]
- Genome editing heralds new era of disease research, therapy - The Augusta Chronicle - January 18th, 2020 [January 18th, 2020]
- Research Fellow in Vascular Stem Cell Biology job with QUEENS UNIVERSITY BELFAST | 195527 - Times Higher Education (THE) - February 10th, 2020 [February 10th, 2020]
- More than skin deep: the latest innovation in 3D printing - Med-Tech Innovation - February 10th, 2020 [February 10th, 2020]
- Examining the link between menopause and heart disease risk - Medical News Bulletin - February 10th, 2020 [February 10th, 2020]
- Women Face an Increased Risk of Heart Disease With AgeRunning Can Help - runnersworld.com - February 12th, 2020 [February 12th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 - Galus Australis - February 15th, 2020 [February 15th, 2020]
- Valentine's Day Matters of the Heart, Biopharma-Style - BioSpace - February 15th, 2020 [February 15th, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Sharon - February 22nd, 2020 [February 22nd, 2020]
- UI at 150 & Beyond: 'The Quad was the best no matter what the weather' - Champaign/Urbana News-Gazette - February 22nd, 2020 [February 22nd, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Dedham - February 23rd, 2020 [February 23rd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Wareham - March 22nd, 2020 [March 22nd, 2020]
- 'Little Foot' skull reveals how this more than 3 million year old human ancestor lived - HeritageDaily - March 22nd, 2020 [March 22nd, 2020]
- It's Not Only About Neurons - The Good Men Project - March 22nd, 2020 [March 22nd, 2020]
- Who is Sir Patrick Vallance and what is his role in government during coronavirus outbreak? - The Scottish Sun - March 22nd, 2020 [March 22nd, 2020]
- University of Washington Pathology Professor Dies of COVID-19 - The Scientist - March 22nd, 2020 [March 22nd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Rochester - March 23rd, 2020 [March 23rd, 2020]
- Ancient human ancestor 'Little Foot' probably lived in trees, new research finds - WBAP News/Talk - March 23rd, 2020 [March 23rd, 2020]
- Study shows similarity in anti-VEGF injection intervals for wet AMD - Ophthalmology Times - March 25th, 2020 [March 25th, 2020]
- aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform - BioSpace - March 25th, 2020 [March 25th, 2020]
- Health researchers find solution to life-threatening side effect - Mirage News - March 25th, 2020 [March 25th, 2020]
- European Vascular Biology Organisation | Advancing human ... - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Program | Boston Children's Hospital - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Research Program | Johns Hopkins ... - March 25th, 2020 [March 25th, 2020]
- Anatomy of a heatwave: how Antarctica recorded a 20.75C day last month - The Conversation AU - April 1st, 2020 [April 1st, 2020]
- Who is Sir Patrick Vallance and is he speaking at todays government coronavirus press briefing? - The Sun - April 1st, 2020 [April 1st, 2020]